Stay updated on Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study record page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:45:46.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    A banner announces that NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during a transition. The page otherwise displays a 403 error rather than the study record.
    Difference
    1%
    Check dated 2026-10-25T15:32:39.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2; the page remains a 403 error screen.
    Difference
    0.2%
    Check dated 2026-10-18T22:08:24.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1 while the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T22:08:59.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study details, indicating the record is currently inaccessible at this URL. This is an access issue rather than a substantive update to the study information.
    Difference
    19%
    Check dated 2026-09-20T19:39:51.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The revision tag on the page was updated from v3.6.5 to v3.6.6, indicating a newer version of the site’s interface. This is an internal version change and does not imply changes to the study data or eligibility information.
    Difference
    0.1%
    Check dated 2026-08-30T22:23:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.